argenx SE
NASDAQ:ARGX
argenx SE
Operating Income
argenx SE
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
argenx SE
XBRU:ARGX
|
Operating Income
-$592.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
AEX:PHARM
|
Operating Income
-$8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Operating Income
-€30.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Income
-$263m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-22%
|
|
Merus NV
NASDAQ:MRUS
|
Operating Income
-$166.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Operating Income
-€3.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is argenx SE's Operating Income?
Operating Income
-592.1m
USD
Based on the financial report for Mar 31, 2024, argenx SE's Operating Income amounts to -592.1m USD.
What is argenx SE's Operating Income growth rate?
Operating Income CAGR 5Y
-44%
Over the last year, the Operating Income growth was 43%. The average annual Operating Income growth rates for argenx SE have been 1% over the past three years , -44% over the past five years .